Want to see BSX full AI Analyst Report?
Revenue by Segment
Breaks down sales by business lines and product families (for example, cardiovascular, rhythm & neuro, endoscopy and urology), highlighting which segments drive revenue and margins. Changes in segment mix indicate where innovation, pricing pressure, or competitive dynamics are helping or hurting the company’s growth and profitability.Cardiology has become the dominant growth driver, but the late-period step-up looks driven more by portfolio reclassification/acquisition effects than steady organic acceleration — important because management explicitly excludes the Penumbra deal from guidance. Urology’s recent lift belies lingering weakness (company expects low‑ to mid‑single‑digit full‑year growth). Endoscopy and neuromodulation deliver steadier, constructive momentum, yet near‑term margins and comparability are clouded by POLARx inventory charges, supply issues and management’s more cautious guidance.
Date | Endoscopy | Urology | Neuromodulation | Cardiology | Peripheral Interventions | Specialty Pharma |
|---|---|---|---|---|---|---|
Jun 30, 2026 | $793.00M | $684.00M | $341.00M | $3.62B | $0.00 | $0.00 |
Mar 31, 2026 | $736.00M | $646.00M | $318.00M | $3.50B | $0.00 | $0.00 |
Dec 31, 2025 | $759.00M | $718.00M | $332.00M | $3.48B | $0.00 | $0.00 |
Sep 30, 2025 | $747.00M | $682.00M | $293.00M | $2.64B | $702.00M | $0.00 |
Jun 30, 2025 | $737.00M | $676.00M | $303.00M | $2.65B | $698.00M | $0.00 |
Mar 31, 2025 | $673.00M | $633.00M | $271.00M | $2.43B | $656.00M | $0.00 |
Dec 31, 2024 | $690.00M | $630.00M | $299.00M | $2.30B | $645.00M | $0.00 |
Sep 30, 2024 | $678.00M | $532.00M | $268.00M | $2.13B | $602.00M | $0.00 |
Jun 30, 2024 | $676.00M | $525.00M | $282.00M | $2.05B | $590.00M | $0.00 |
Mar 31, 2024 | $642.00M | $513.00M | $256.00M | $1.87B | $573.00M | $0.00 |